Business
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis. The exclusive event, hosted by Red
About this update from Enlivex Ltd.
[{"type":"image","alt":"Enlivex Therapeutics Ltd","displaySize":"","headline":null,"caption":"Enlivex Therapeutics Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lp55OoyoIVpO2pUDVuohlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31","width":150,"height":42}},"lazy":false},{"type":"text","content":"Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis.","length":470,"tagName":"p"},{"type":"text","content":"The exclusive event, hosted by RedChip Companies, will feature the Company’s Chief Executive Officer, Oren Hershkovitz Ph.D., who will provide a detailed review of the interim results, which demonstrated a statistically significant 47.0% average reduction in reported pain (P=0.0001) and a 46% improvement in joint function at six months post-treatment. Additionally, 83% of treated patients were still considered responders to treatment at six months, which the Company believes highlights the durability and sustained efficacy of Allocetra™ as a potential breakthrough treatment for osteoarthritis. Importantly, no serious adverse events were reported, reinforcing the favorable safety profile of Allocetra™.","length":710,"tagName":"p"},{"type":"text","content":"Dr. Hershkovitz commented, “We are excited by these promising interim results, which showcase Allocetra™’s potential to deliver meaningful and sustained, pain relief for patients suffering from moderate to severe knee osteoarthritis. The consistency and durability of the efficacy data—combined with the safety profile—underscore Allocetra™’s promising potential to become a novel treatment in a space with urgent unmet medical needs. We remain deeply committed to advancing this innovative therapy and unlocking its full potential for mill...